ClinicalTrials.gg

Program

vedolizumab

Also written as “Vedolizumab”, “Vedolizumab IV” and “Vedolizumab SC”.

Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Pouchitis · Melanoma · Cholangitis, Sclerosing, led by 2 companies.

Furthest: phase 4, since Sep 23, 201552 company-led studies, 13 open or runningNext primary completion: May 1, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda5112 open or runningphase 4since Sep 23, 2015Feb 11, 2008May 1, 2027phase 4 · NCT06581328
AbbVie11 open or runningphase 3since Mar 12, 2025Mar 12, 2025Aug 2027phase 3 · NCT06880744

Also a collaborator on its studies: takeda-development-center-americas-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Feb 11, 2008.

  1. Aug 30, 2018Phase 3 study in Hematopoietic Stem CellsTakeda · NCT03657160 · 343 enrolled · United States, Argentina, Australia and more
  2. May 10, 20194 phase 1 studies in Healthy VolunteersTakeda · NCT03949621, NCT03948581, NCT03961308 and 1 more
  3. Feb 2, 2021Phase 3 study in Colitis, UlcerativeTakeda · NCT04738942 · 56 enrolled · Japan
  4. Mar 1, 20212 phase 3 studiesTakeda · NCT04779320, NCT04779307
  5. Mar 15, 2021Phase 4 study in Colitis, UlcerativeTakeda · NCT04804540 · 150 enrolled · India
  6. Jun 30, 2022Phase 3 study in Colitis, UlcerativeTakeda · NCT05442567 · 240 planned · United States, Australia, Belgium and more
  7. Apr 20, 2023Phase 3 study in Crohn DiseaseTakeda · NCT05837897 · 408 planned · China
  8. Sep 13, 2023Phase 4 study in Crohn DiseaseTakeda · NCT06045754 · 50 enrolled · United States, Canada
  9. Oct 17, 2023Phase 3 study in Colitis, UlcerativeTakeda · NCT06100289 · 70 planned · United States, Belgium, Bulgaria and more
  10. Oct 18, 2023Phase 4 study in Colitis, UlcerativeTakeda · NCT06095128 · 60 enrolled · United States, Canada
  11. Jan 19, 2024Phase 3 study in Crohn DiseaseTakeda · NCT06227910 · 396 planned · United States, Austria, Belgium and more
  12. May 3, 20242 phase 3 studiesTakeda · NCT06405087, NCT06443502
  13. Aug 30, 2024Phase 4 study in Colitis, UlcerativeTakeda · NCT06581328 · 200 planned · United States
  14. Mar 12, 2025AbbVie's first study: phase 3 study in Colitis, UlcerativeNew to AbbVieAbbVie · NCT06880744 · 573 enrolled · United States, Austria, Bulgaria and more

Ahead

  1. May 1, 2027Primary completion: phase 4 study in Colitis, UlcerativeTakeda · NCT06581328
  2. Jun 8, 2027Primary completion: phase 3 study in Crohn DiseaseTakeda · NCT06227910
  3. Jun 28, 2027Primary completion: phase 4 study in Crohn DiseaseTakeda · NCT06045754
  4. Jul 9, 2027Primary completion: phase 4 study in Colitis, UlcerativeTakeda · NCT06095128

TargetBeta

ITGA4 →ITGB7 →read by rule
“Integrin alpha-4/beta-7 inhibitor”ChEMBL 37, by rule

Studies

All 52 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06880744Colitis, Ulcerative · United States, Austria, Bulgaria and more3Active, not recruitingAbbVieAug 2027573
NCT06581328Colitis, Ulcerative · United States4RecruitingTakedaMay 1, 2027200
NCT06443502Pouchitis · Belgium, Croatia, Czechia and more3RecruitingTakedaJan 31, 203030
NCT06405087Colitis, Ulcerative · United States, Belgium, Bulgaria and more3RecruitingTakedaAug 12, 203070
NCT06227910Crohn Disease · United States, Austria, Belgium and more3RecruitingTakedaJun 8, 2027396
NCT06095128Colitis, Ulcerative · United States, Canada4Active, not recruitingTakedaJul 9, 202760
NCT06100289Colitis, Ulcerative · United States, Belgium, Bulgaria and more3RecruitingTakedaMay 16, 202870
NCT06045754Crohn Disease · United States, Canada4Active, not recruitingTakedaJun 28, 202750
NCT05837897Crohn Disease · China3RecruitingTakedaMar 8, 2030408
NCT05442567Colitis, Ulcerative · United States, Australia, Belgium and more3RecruitingTakedaFeb 7, 2033240
NCT04804540Colitis, Ulcerative · India4CompletedTakedaFeb 2, 2024150
NCT04779320Crohn Disease · United States, Australia, Belgium and more3RecruitingTakedaSep 13, 2027120
NCT04779307Colitis, Ulcerative · United States, Australia, Belgium and more3CompletedTakedaJul 1, 2025121
NCT04738942Colitis, Ulcerative · Japan3Active, not recruitingTakedaMay 30, 202556
NCT03961308Healthy Volunteers · United States1CompletedTakedaOct 20, 2018204
NCT03961295Healthy Volunteers · United States1CompletedTakedaJul 14, 201824
NCT03949621Healthy Volunteers · United States1CompletedTakedaJul 2, 201824
NCT03948581Healthy Volunteers · United States1CompletedTakedaAug 14, 2018102
NCT03657160Hematopoietic Stem Cells · United States, Argentina, Australia and more3CompletedTakedaFeb 7, 2022343
NCT03329209Colitis, Ulcerative · China1CompletedTakedaJul 26, 201816
NCT03234907Crohn Disease · China3CompletedTakedaAug 14, 2020215
NCT03221036Moderately to Severely Active Ulcerative Colitis · China3Active, not recruitingTakedaSep 24, 2027392
NCT03196427Colitis, Ulcerative · United States, France, Hungary and more2CompletedTakedaApr 3, 202559
NCT03138655Colitis, Ulcerative · United States, Belgium, Canada and more2CompletedTakedaMar 31, 202089
NCT03035058Cholangitis, Sclerosing3WithdrawnTakedaSep 20200
NCT03029143Colitis, Ulcerative · United States, Canada4CompletedTakedaOct 16, 2020278
NCT02993783Allogeneic Hematopoietic Stem Cell Transplantation · United States, Belgium, France and more2TerminatedTakedaMay 9, 201817
NCT02913508Colitis, Ulcerative2WithdrawnTakedaDec 20150
NCT02790138Pouchitis · United States, Belgium, Canada and more4CompletedTakedaJun 11, 2020102
NCT02764762Crohn Disease · United States, Canada4CompletedTakedaSep 22, 202055
NCT02760615Colitis, Ulcerative · United States4WithdrawnTakedaAug 1, 20200
NCT02743806Colitis, Ulcerative · Australia, Bulgaria, Czechia and more4TerminatedTakedaJan 3, 2023331
NCT02728895Allogeneic Hematopoietic Stem Cell Transplantation · United States1CompletedTakedaJul 10, 201824
NCT02723006Melanoma · United States1TerminatedTakedaMay 11, 201822
NCT02630966Crohn Disease · United States, Canada, France and more4CompletedTakedaSep 4, 201834
NCT02620046Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedTakedaJun 12, 2024746
NCT02611830Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedTakedaMay 30, 2018383
NCT02611817Crohn Disease · United States, Australia, Belgium and more3CompletedTakedaMay 6, 2019644
NCT02559713Colitis, Ulcerative · United States4CompletedTakedaFeb 22, 201911
NCT02497469Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedTakedaSep 26, 2018771
NCT02425111Crohn Disease · United States, Belgium, Canada and more3CompletedTakedaJun 2, 2017101
NCT02163421Healthy · United Kingdom1CompletedTakedaDec 201448
NCT02039505Colitis, Ulcerative · Japan3CompletedTakedaFeb 27, 2018292
NCT02038920Crohn Disease · Japan3CompletedTakedaJan 25, 2019157
NCT01981616Inflammatory Bowel Diseases · United Kingdom1CompletedTakedaMay 2012127
NCT01224171Crohn Disease · United States, Canada3CompletedTakedaFeb 2012416
NCT01177228Colitis, Ulcerative2CompletedTakedaJun 200847
NCT00790933Colitis, Ulcerative · United States, Australia, Belgium and more3CompletedTakedaOct 31, 20172,243
NCT00783718Colitis, Ulcerative · United States, Canada, Puerto Rico3CompletedTakedaDec 2011895
NCT00783692Crohn Disease · United States, Canada, Puerto Rico3CompletedTakedaMar 20121,116
NCT00655135Crohn Disease2CompletedTakedaJun 2002185
NCT00619489Colitis, Ulcerative · Canada2CompletedTakedaMar 201072

How it is read

Names in the registry

  • “Vedolizumab”, 27 entries
  • “Vedolizumab IV”, 9 entries
  • “Vedolizumab SC”, 9 entries
  • “vedolizumab”, 5 entries
  • “Vedolizumab 108 mg SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.